NTLA Intellia Therapeutics, Inc.

NASDAQ
$9.52

Intellia Therapeutics, Inc. (NTLA) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.75 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.4% since its last earnings release on November 5, 2026.

Intellia Therapeutics Missed Consensus Estimates
Thursday, November 5, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.75)
Rev est $24.32M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.45

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Intellia Therapeutics, Inc.

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.?

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.